A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy

Caitlyn T. Solem, Timothy J. Bell, Youngmin Kwon, Joseph C. Cappelleri, Courtney Johnson, Helen Bhattacharyya, Caroline J. Hoang, Jorge E. Cortes

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy'. Together they form a unique fingerprint.

Medicine & Life Sciences